Tampier Lutske, Quintanilla María Elena, Israel Yedy
Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Alcohol Clin Exp Res. 2008 Jun;32(6):937-41. doi: 10.1111/j.1530-0277.2008.00658.x. Epub 2008 Apr 26.
Disulfiram, an inhibitor of aldehyde dehydrogenase used in the treatment of alcoholism, is an effective medication when its intake is supervised by a third person. However, its therapeutic efficacy varies widely, in part due to the fact that disulfiram is a pro-drug that requires its transformation into an active form and because it shows a wide range of secondary effects which often prevent the use of doses that ensure full therapeutic effectiveness. In this preclinical study in rats we report the development of tolerance to disulfiram induced by the chronic ingestion of ethanol, an additional source of variation for the actions of disulfiram with possible therapeutic significance, We also addresses the likely mechanism of this effect.
Wistar-derived rats bred for generations as high ethanol drinkers (UChB) were trained for either 3 days (Group A) or 30 days (Group B) to choose between ethanol (10% v/v) or water, which were freely available from 2 bottles on a 24-hour basis. Subsequently, animals in both groups were administered disulfiram or cyanamide (another inhibitor of aldehyde dehydrogenase) and ethanol intake in this free choice paradigm was determined. Animals were also administered a standard dose of 1 g ethanol/kg (i.p) and arterial blood acetaldehyde was measured.
Disulfiram (12.5 and 25 mg/kg) and cyanamide (10 mg/kg) markedly inhibited ethanol intake (up to 60 to 70%) in animals that had ethanol access for only 3 days (Group A). However both drugs were inactive in inhibiting ethanol intake in animals that had consumed ethanol for 30 days (Group B). Following the injection of 1 g ethanol/kg, arterial blood acetaldehyde levels reached levels of 150 and 300 microM for disulfiram and cyanamide respectively, values which were virtually identical regardless of the length of prior ethanol intake of the animals.
Chronic ethanol intake in high-drinker rats leads to marked tolerance to the aversive effects of disulfiram and cyanamide on ethanol intake despite the presence of consistently high levels of blood acetaldehyde. These findings may have implications for the use of disulfiram for the treatment of alcoholism in humans.
双硫仑是一种用于治疗酒精中毒的乙醛脱氢酶抑制剂,在由第三方监督摄入时是一种有效的药物。然而,其治疗效果差异很大,部分原因在于双硫仑是一种前体药物,需要转化为活性形式,并且它表现出广泛的副作用,这常常阻碍使用能确保充分治疗效果的剂量。在这项针对大鼠的临床前研究中,我们报告了长期摄入乙醇诱导产生对双硫仑的耐受性,这是双硫仑作用的另一个变异来源,可能具有治疗意义。我们还探讨了这种效应的可能机制。
将经过多代培育的作为高乙醇饮用者的Wistar大鼠(UChB)训练3天(A组)或30天(B组),使其在乙醇(10% v/v)和水之间进行选择,两种液体24小时均可从两个瓶子中自由获取。随后,给两组动物施用双硫仑或氨甲丙二酯(另一种乙醛脱氢酶抑制剂),并在这种自由选择模式下测定乙醇摄入量。还给动物腹腔注射1 g乙醇/kg的标准剂量,并测量动脉血中的乙醛含量。
双硫仑(12.5和25 mg/kg)和氨甲丙二酯(10 mg/kg)显著抑制仅接触乙醇3天的动物(A组)的乙醇摄入量(高达60%至70%)。然而,这两种药物对已摄入乙醇30天的动物(B组)的乙醇摄入抑制无效。注射1 g乙醇/kg后,双硫仑和氨甲丙二酯使动脉血乙醛水平分别达到150和300 microM,无论动物先前摄入乙醇的时长如何,这些值实际上是相同的。
尽管血液乙醛水平持续较高,但高饮酒量大鼠长期摄入乙醇会导致对双硫仑和氨甲丙二酯对乙醇摄入的厌恶效应产生显著耐受性。这些发现可能对双硫仑在人类酒精中毒治疗中的应用具有启示意义。